From Yahoo Finance: 2025-03-22 13:56:00

Iovance Biotherapeutics, a biotech company with promising cancer therapies, has seen its stock drop by 74% over the past year. Despite this, Wall Street analysts are optimistic, with price targets ranging from $6 to $32 per share.

The company’s flagship medicine, Amtagvi, was approved by the FDA for melanoma treatment last year. However, the lengthy 34-day manufacturing process and specialized administration present challenges for widespread use and profitability.

Iovance reported $164.1 million in revenue in 2024, with plans to expand Amtagvi’s approval to more countries. The company estimates a potential market of 20,000 melanoma patients in the U.S. alone, with a global market of 325,000 cases annually.

Despite concerns about profitability and regulatory hurdles, Iovance shows promise with plans to keep cash burn under $300 million in 2025. The company aims to expand Amtagvi’s indications and reach, potentially becoming a blockbuster drug in the next few years.

Investors should consider the risks and potential rewards of investing in Iovance. The company’s innovative therapies and market potential could lead to significant growth, but caution is advised due to clinical and regulatory uncertainties.

For more information on the top 10 stocks recommended by The Motley Fool Stock Advisor team, including potential high-growth opportunities, investors can explore the latest list. Past recommendations have resulted in significant returns, highlighting the value of thorough research and investment strategy.

Read more: 1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street